Christopher M. Todoroff Senior Vice President and General Counsel Humana Inc. 500 West Main Street Louisville, Kentucky 40202

Re: Humana Inc.

Form 10-K for the year ended 12/31/2009

Filed February 19, 2010 File No. 001-05975

Dear Mr. Todoroff:

We have reviewed your filing and have the following comments. Where the comments request you to revise disclosure, the information you provide should show us what the revised disclosure will look like and identify the annual or quarterly filing, as applicable, in which you intend to first include it. If you do not believe that revised disclosure is necessary, explain the reason in your response. After reviewing the information provided, we may raise additional comments and/or request that you amend your filing.

Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comment or on any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter.

## Form 10-K for the Fiscal Year Ended December 31, 2009

1. We have not yet reviewed the Part III information that is included in your Form 10-K. We may have further comments after reviewing that information and we will not be able to clear our review of your filing until we have the opportunity to resolve any resulting comments.

Christopher M. Todoroff Humana Inc. March 23, 2010 Page 2 of 3

## Unregistered Sales of Equity Securities and Use of Proceeds, page 31

- 2. With regard to your disclosure of sales of unregistered common shares under your two retirement plans, please:
  - Disclose the number of unregistered shares sold beyond the limit of the Humana Retirement and Savings Plan, the number of unregistered shares sold under the Humana Puerto Rico 1165(e) Retirement Plan and the timeframe during which any shares were issued without registration; and
  - Provide an analysis as to why the effect of these unregistered issuances, including
    the exercise of any applicable rescission rights, or the risk of litigation, monetary
    fines or other regulatory sanctions will not materially impact your results of
    operations, financial position, or cash flows.

\* \* \*

Please respond to these comments within 10 business days or tell us when you will provide us with responses. Please furnish a letter that keys your response to our comments and provide the requested information. Detailed letters greatly facilitate our review. Please furnish your letter on EDGAR under the form type label CORRESP.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes all information required under the Securities Exchange Act of 1934 and that they have provided all information investors require for an informed investment decision. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

In connection with responding to our comments, please provide, in your letter, a statement from the company acknowledging that:

- the company is responsible for the adequacy and accuracy of the disclosure in the filing;
- staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
- the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in our review of your filing or in response to our comment on your filing.

Christopher M. Todoroff Humana Inc. March 23, 2010 Page 3 of 3

Please contact Michael Rosenthall at (202) 551-3674 or me at (202) 551-3715 with any questions.

Sincerely,

Jeffrey P. Riedler Assistant Director